阿普斯特用于治疗银屑病关节炎的疗效和安全性的Meta分析

发布时间：2018-06-01 14:37

本文选题：银屑病关节炎 + 阿普斯特　；参考：《中国医院药学杂志》2017年20期

【摘要】：目的:评价阿普斯特(apremilast,APR)治疗银屑病关节炎(psoriatic arthritis,PsA)的有效性和安全性。方法:检索"PubMed"、"Cochrane Library"、"OVID"公开发表的相关研究,并查询"clinictrials.gov"。进行文献质量评价和资料提取,用Rev Man5.3.5软件进行Meta分析。结果:共纳入随机对照试验(randomized controlled trial,RCT)文献6篇,共计1 645例PsA患者。Meta分析结果显示,在治疗PsA的有效性方面,治疗12周或16周后,APR各剂量组合并后ACR20缓解率高于安慰剂对照组,RR=1.67[95%CI(1.36,2.05),P0.000 01];HAQ-DI(Health assessment questionnaire-disability index)也优于安慰剂对照组,WMD=-0.14[95%CI(-0.17,-0.11),P0.000 01]。在安全性方面,APR各剂量组合并后不良事件(adverse event,AEs)发生率高于安慰剂对照组,RR=1.91[95%CI(1.41,2.59),P0.000 1]。结论:APR治疗可有效延缓或改善PsA病情,虽然导致不良反应,但患者耐受性良好。
[Abstract]:Objective: to evaluate the efficacy and safety of APR in the treatment of psoriatic arthritis. Methods: research published in PubMed, Cochrane Library and OVID was retrieved and clinictrials.gov was queried. Literature quality evaluation and data extraction, Rev Man5.3.5 software for Meta analysis. Results: a total of 1 645 cases of PsA patients. Meta-analysis showed that it was effective in the treatment of PsA. After 12 or 16 weeks of treatment, the remission rate of ACR20 in each dose group was higher than that in the placebo control group (RRN 1.67 [95 CI 1.36 卤2.05 P0.00001] HAQ-DIHealth assessment questionnaire-disability indexs), and was also superior to that in the placebo control group (WMD-0.14 [95CI-0.17- 0.11] P0.00001]. In terms of safety, the incidence of adverse events associated with adverse events in the APR groups was higher than that in the placebo control group. Conclusion the treatment of PsA can effectively delay or improve the condition of PsA, although it leads to adverse reactions, the patient has good tolerance.
【作者单位】：华中科技大学同济医学院附属武汉中心医院药学部;华中科技大学同济医学院附属同济医院药学部;
【基金】：武汉市科技局晨光计划(编号:2014070404010226) 武汉市中青年人才计划
【分类号】：R684.3;R758.63

【相似文献】